C12N 2740/16042
Virus or viral particle as vehicle
Official title: virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N2740/16042 (Virus or viral particle as vehicle) appears on 14 US grants and 30 published applications in this corpus.
Search patents in C12N- Granted patents
- 14
- Published applications
- 30
- Assignees
- 30
- Inventors
- 59
- Latest grant
- 16 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2007 | 0 | 1 |
| 2008 | 0 | 0 |
| 2009 | 0 | 1 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 1 | 2 |
| 2013 | 2 | 0 |
| 2014 | 0 | 0 |
| 2015 | 0 | 2 |
| 2016 | 1 | 0 |
| 2017 | 0 | 1 |
| 2018 | 0 | 3 |
| 2019 | 2 | 4 |
| 2020 | 2 | 2 |
| 2021 | 2 | 2 |
| 2022 | 2 | 3 |
| 2023 | 0 | 3 |
| 2024 | 1 | 3 |
| 2025 | 0 | 1 |
| 2026 | 1 | 2 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Virus-like particle16 Jun 2026US 12,655,388 B2Autolus Limited
- Virus-like particles and use thereof10 Sep 2024US 12,084,698 B2Kyoto University
- Method and system for inactivating virus infectivity for producing live-attenuated vaccines12 Jul 2022US 11,382,967 B2George Mason University
- Virus-like particle (VLP) based small molecule-protein interaction trap25 Jan 2022US 11,231,416 B2Universiteit Gent
- Retroviral particle comprising at least two encapsidated nonviral RNAs21 Sep 2021US 11,124,775 B2Flash Therapeutics
- Crystalline-protein-based platform using viral nucleocapsid for producing target-protein-fused self-assembled nanoparticles9 Jul 2026US 2026/0193661 A1University-Industry Foundation, Yonsei University
- Compositions and Methods for Targeted Delivery of CRISPR-CAS Effector Polypeptides19 Feb 2026US 2026/0048143 A1The Regents of the University of California
- Syncitin-1 fusion proteins and uses thereof for cargo delivery into target cells10 Jul 2025US 2025/0223326 A1Assistance Publique-HôPitaux De Paris (Aphp)
- Compositions and methods for use in immunotherapy26 Dec 2024US 2024/0424090 A1Inserm (Institut National De La Sante Et De La Recherche Medicale)
- Differential cxcr4 expression on hematopoietic progenitor cells versus stem cells directs homing and long-term engraftment5 Sep 2024US 2024/0293466 A1Children's Hospital Medical Center
Most cited
By later US patents
- Lentiviral triplex DNA, and vectors and recombinant cells containing lentiviral triplex DNA17US 10,407,695 B2Centre National De La Recherche Scientifique · 2019
- Lentiviral triplex DNA, and vectors and recombinant cells containing lentiviral triplex DNA16US 8,093,042 B2Institut National de la Sante et de la Recherche Medicale · 2012
- Retroviral particle comprising at least two encapsidated nonviral RNAs4US 11,124,775 B2Flash Therapeutics · 2021
- Lentiviral triplex DNA, and vectors and recombinant cells containing lentiviral triplex DNA3US 8,512,993 B2Centre National De La Recherche Scientifique · 2013
- Lentiviral triplex DNA, and vectors and recombinant cells containing lentiviral triplex DNA3US 8,512,994 B2Centre National De La Recherche Scientifique · 2013